The OS has increased significantly over the past few months, hence my dilution comments. OS isn’t anything out of the ordinary, but the increase is when taking into account volume.
Listen, they’re not generating material revenue here to survive, so they have to go after toxic debt. They have to do what they believe is necessary in that case.
In the case of investors, one would hope that the dilution doesn’t hinder the price too much. Well it certainly has, and if it weren’t for the countless paid promos they signed up for, this would be under a penny right now.
The price fell from the .30 range to around .05 in the matter of a few weeks with only good news coming out because they dumped millions of shares in the market in a very short time frame. Not very investor friendly. They did what they thought was necessary, and IMO the investors then did what they thought was necessary and many stopped buying, hence the days where volume was literally non-existant. They try to help prop the volume up anytime they need to dilute more by two ways: paid promos (hit and miss) and “news” which many times lowers the price substantially because they dump way too much with only a slight increase in volume.
This is what it’s always been, a company scraping away with the hopes that one day their vaccine makes it through phase 2 and into phase 3, then hopefully approval. It’s a long shot with all of these companies since it’s so damn difficult to get approved. They have tried to differentiate their product line to create revenue but it’s been a slow process that I’m still waiting to see how impactful those actions will be to the bottom line.
Don’t know what else to say tbh, if you’re in this for the long run then just don’t look at the price at all and hope that one day this hits it big. Just don’t invest more than you can afford to lose.
